Acadia Pharmaceuticals ACAD Return on invested capital

Return on invested capital at other companies

BiogenBIIB

4.6%-3.5pp

Neurocrine BiosciencesNBIX

17.5%+5.1pp

Taysha Gene Therapies, Inc.TSHA

-6,605%—

Zevra Therapeutics, Inc.ZVRA

71.7%+48.7pp

Rapport Therapeutics, Inc.RAPP

-52.1%+9.1pp

Amneal Pharmaceuticals, Inc.AMRX

20.3%+10.3pp

FAQ

What is Acadia Pharmaceuticals's return on invested capital?

Acadia Pharmaceuticals (ACAD) reported return on invested capital of 10.7% in Q2 2026.

How has Acadia Pharmaceuticals's return on invested capital changed year-over-year?

Acadia Pharmaceuticals's return on invested capital decreased by 72.3% year-over-year, from 38.4% to 10.7%.

What is the long-term trend for Acadia Pharmaceuticals's return on invested capital?

Over 4 years (2020 to 2025), Acadia Pharmaceuticals's return on invested capital has grown at a -32.9% compound annual growth rate (CAGR), from -65.9% to 13.4%.

What does return on invested capital mean?

Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.